PTC Therapeutics reports Q3 EPS ($1.39), consensus ($1.44)

Reports Q3 revenue $197M, consensus $172.65M. “I am proud of our team’s strong execution,” said Matthew Klein, CEO. “We continue to achieve excellent revenue performance allowing us to raise full-year revenue guidance. In addition, we have submitted three approval applications to FDA so far this year, all of which have been accepted for review, and plan a fourth submission for vatiquinone for Friedreich ataxia in December. We are on our way to accomplishing all of our 2024 objectives and are in a strong financial position to execute on our long-term strategic plans.”